In vivo Nanoplatforms for Diagnostics (IVN:Dx)

The summary for the In vivo Nanoplatforms for Diagnostics (IVN:Dx) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the DARPA Microsystems Technology Office, which is the U.S. government agency offering this grant.

In vivo Nanoplatforms for Diagnostics (IVN:Dx): The specific objective of the In vivo Nanoplatforms for Diagnostics (IVN:Dx) thrust of the In vivo Nanoplatforms (IVN) program is to develop biocompatible nanosensors that provide continuous, noninvasive, and highly accurate measurement of a variety of conditions and substances within the living tissue of animals, plants, and insects using non-toxic materials with limited immunogenicity. These sensors will permit qualitative and quantitative assessment over large concentration ranges of both small (e.g., glucose, lactate, and urea) and large molecules (e.g., proteins, oligonucleotides, infectious agents, and chemical/biological threat agents) in the organism and environment through optical, electronic, thermal or magnetic mechanisms. See full DARPA-BAA-12-33 attached.